The administration of riboflavin produced the amelioration of symptoms in patients affected by multiple acyl CoA dehydrogenase deficiency (MADD) caused by mutations at the electron-transport flavoprotein dehydrogenase (ETFDH) or in the electron transfer flavoprotein (ETF) consisting of α and β subunits encoded by ETFA and ETFB, respectively [64,65,66]. This evidence concerns the gene ETFB and multiple acyl-CoA dehydrogenase deficiency.